@ha.dley's Zepbound journey, fact-checked

TikTok creator @ha.dley shared her 10-month weight loss journey on Zepbound (tirzepatide), showing what appears to be significant physical changes in a before-and-after comparison. While she doesn't make explicit medical claims in this particular video, her transformation matches what clinical trials show about tirzepatide's effects.

What does this video actually claim?

The video shows @ha.dley's physical transformation after 10 months on Zepbound, though she originally planned to wait a full year before posting. She doesn't state specific numbers or make direct medical claims in this post.

The visual comparison suggests substantial weight loss over the 10-month period. Her caption focuses on the practical frustration of losing TikTok drafts when switching phones rather than making bold promises about the medication.

By using hashtags like #zepboundjourney and #weightlosstransformation, she's positioning her experience within the broader social media conversation about GLP-1 medications for weight management.

Does her timeline match what studies show?

Her 10-month timeline falls within the range of major tirzepatide trials, though peak effects typically occur earlier. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) tracked participants for 72 weeks, finding maximum weight loss around 60-68 weeks.

At 10 months (roughly 40 weeks), participants in SURMOUNT-1 had already achieved most of their eventual weight loss. Those on the highest 15mg dose averaged 20.9% body weight reduction by 72 weeks.

The visual change @ha.dley shows could reasonably align with these trial results, though individual responses vary significantly. Some people plateau earlier, others continue losing weight past the one-year mark.

What context is missing from her post?

While @ha.dley doesn't make false claims, her post lacks important context about tirzepatide treatment. She doesn't mention the medication's side effects, which affected 89% of participants in SURMOUNT-1.

The most common issues include nausea (experienced by 43% of participants), diarrhea (23%), and constipation (24%). About 16% of people discontinued treatment due to side effects.

Her transformation also doesn't address the lifestyle changes that typically accompany successful GLP-1 treatment. The trials combined medication with reduced-calorie diets and exercise counseling, not medication alone.

Is this typical for Zepbound users?

@ha.dley's apparent results fall within the range seen in clinical trials, though we can't verify her specific weight loss percentage from the video alone. In SURMOUNT-1, individual results varied widely even on the same dose.

About 91% of participants lost at least 5% of their body weight, while 57% achieved 20% or greater weight loss on the highest dose. This wide range means some people see dramatic changes like @ha.dley appears to show, while others see more modest results.

Her experience represents one data point, not a guarantee of typical results. The trial data provides a better sense of what most people can expect than any single social media post.

What should potential users know?

Tirzepatide (Zepbound) is FDA-approved for chronic weight management in adults with obesity or overweight with related health conditions. The medication requires a prescription and ongoing medical supervision.

Treatment typically starts at 2.5mg weekly, increasing gradually to minimize side effects. The maintenance dose ranges from 5mg to 15mg weekly, depending on individual response and tolerance.

Cost remains a significant barrier. Without insurance coverage, Zepbound can cost over $1,000 monthly. Insurance approval often requires meeting specific BMI criteria and having weight-related health conditions.